In The News

SystImmune, Inc. to Present New Data from Oncology Programs at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2023

Redmond, Washington May 1st, 2023

Leaders in Breast and Lung Cancer treatment join SystImmune, Inc.’s Clinical Science Advisory Committee

Redmond, Washington April 26th, 2023

SystImmune, Inc. to Present Data from Seven Preclinical Programs at the American Association of Cancer Research (AACR) Annual Meeting 2023

Redmond, Washington April 14th, 2023

Biokin Pharmaceutical Launches Shanghai Initial Public Offering

Chengdu, China Jan, 2023

Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer

Redmond, Washington May 13rd, 2022

SystImmune, Inc. Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer

Redmond, Washington February 7th, 2022

Systimmune, Inc. Announces SI-F019 As a Blocker of Viral Entry against SARSCoV-2 with Reduced Inflammatory Risk

Redmond, Washington March, 2020

High Throughput Application of High Resolution LC-MS for Upstream and Downstream Biotherapeutics Process Development

Pleasanton, California August, 2018

ACS National Meeting 2018 - Rapid aggregate reduction of bi-specific antibody model by filtration

New Orleans, Louisiana March, 2018